Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Work Strand 4 focuses on stratification through characterisation of host immune responses

test tubesThere is extensive evidence that the outcome of HCV infection is dependent on host innate and adaptive immune responses. Analyses of innate activation at the level of both gene expression and protein production can already provide important information predictive of treatment outcome with both current and DAA- based regimens.

There is a strong rationale for further defining the role of innate and adaptive immunity, relevant not only directly to patient stratification but also to the underpinning mechanisms of host control. This is particularly relevant to genotype-3, since most studies to date have focused on genotype-1 infection.

The objective of this Work Strand is to undertake studies to link host immune responsiveness to clinical outcomes.

This Work Strand is led by Professor Paul Klenerman (University of Oxford).